Novartis AG (NVS)

Industry Drug Manufacturers - General

This stock can be held in an Investment ISA and an Investment Account

Sell

$128.94

Buy

$135.00

arrow-up$0.21 (+0.16%)

Prices updated at 13 Dec 2025, 00:11 EST

Prices minimum 15 mins delay

Prices in USD

Novartis AG is a part of the healthcare industry. Its main activity is to research and develop healthcare products and pharmaceuticals such as oncology medicines, generic and biosimilar medicines and eye care devices.

S&P 500

-1.07%

NYSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Drug Manufacturers - General

Chairman

Mr. Simon E Moroney, D.Phil.

CEO

Dr. Vasant Narasimhan

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

75,883

Head office

Lichtstrasse 35

Basel

Switzerland

4056

+41 613241111

investor.relations@novartis.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. William Thomas Winters Independent Director	-
Mr. Frans Van Van Houten, M.Sc. Independent Director	0.11m
Dr. Joerg Reinhardt, PhD Chairman of the Board	1.90m
Ms. Bridgette P. Heller Independent Director	0.22m
Mr. John Douglas Young Independent Director	0.19m
Ms. Ana de Pro Gonzalo Independent Director	0.20m
Mr. Patrice Bula Lead Independent Director	0.21m
Ms. Elizabeth Doherty Independent Director	0.23m
Mr. Harry Kirsch Chief Financial Officer	1.13m
Dr. Charles L. Sawyers Independent Director	0.18m
Dr. Nancy C. Andrews, M.D.,PhD Independent Director	0.18m
Mr. Ton Buechner Independent Director	0.04m
Dr. Vasant Narasimhan Chief Executive Officer	1.87m
Dr. Steffen Lang, PhD President, Operations	-
Dr. Klaus Moosmayer, PhD Chief Ethics, Risk and Compliance Officer	-
Dr. Shreeram Aradhye, M.D. President, Development and Chief Medical Officer	-
Mr. Victor Bulto President, US	0.87m
Mr. Simon E Moroney, D.Phil. Vice Chairman of the Board	0.23m
Ms. Karen L. Hale Chief Legal Officer	-
Mr. Robert Kowalski Chief People and Organization Officer	-
Mr. Daniel Hochstrasser Independent Director	0.20m
Dr. Aharon Gal, PhD Chief Strategy and Growth Officer	-
Dr. Fiona H. Marshall, PhD President, Biomedical Research	-
Dr. Patrick Horber, M.D. President, International	1.00m

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Dodge & Cox	10,585,145
PRIMECAP Management Company	9,341,854
Dimensional Fund Advisors, Inc.	8,840,686
Dodge & Cox Stock Fund	8,142,808
Morgan Stanley - Brokerage Accounts	7,728,873

Director dealings

Date chevron-l-regular chevron-r-regular	Action
No data

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.